SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced progress on the Company’s Rapid Acceleration of Diagnostics (RADx)
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif. , Aug.
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected for $37 Million Project under
License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to
Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies SOUTH SAN FRANCISCO, Calif. , July 31, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Test Intended to Expand Availability of COVID-19 Screening Resources in Central Ohio Workflow with Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Increasing Number of Labs Adopting the Fluidigm High-Throughput Testing Model SOUTH SAN FRANCISCO, Calif., and COLUMBUS, Ohio ,
SOUTH SAN FRANCISCO, Calif. , July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report second quarter 2020 financial results on Thursday,
Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States Study May Inform Recommendations for COVID-19 Care, New Strategies for Treatments SOUTH SAN FRANCISCO, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an
iGLS Among Labs Chosen by Spanish Health Authorities to Expand SARS-CoV-2 Screening End-to-End Workflow from Extraction through Real-Time PCR Using Fluidigm Microfluidics Technology and Reagents Screening of Critical Populations Under Way , Capacity of Up to 6,000 Tests Per Day on Single Instrument
